MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.
Blood Adv
; 1(19): 1467-1472, 2017 Aug 22.
Article
em En
| MEDLINE
| ID: mdl-29296788
ABSTRACT
PARP1 is required for the maintenance of MLL-AF9 leukemias.PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Diagnostic_studies
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article